Does Insurance Cover Ozempic? What Commercial Plans, Medicare, and Medicaid Actually Pay in 2026

Key Takeaways (highlighted box)

• Most commercial insurance plans cover Ozempic when prescribed for type 2 diabetes, usually with prior authorization.
• Almost no commercial plan covers Ozempic when prescribed off-label for weight loss; the FDA-approved weight-loss version is Wegovy.
• Medicare Part D covers Ozempic for diabetes only. Medicare does not cover GLP-1 medications for weight management.
• State Medicaid programs vary; about 80% cover Ozempic for diabetes with prior authorization, almost none for weight loss.
• Without insurance, cash price runs $940 to $1,150 per month; the Novo Nordisk savings card can drop eligible commercial copays to $25.

Direct answer (40-60 words)

Yes, most commercial insurance plans cover Ozempic when it is prescribed for type 2 diabetes, typically with prior authorization and a Tier 3 or Tier 4 copay. Coverage for weight loss is rare because Ozempic is not FDA-approved for that indication. Medicare Part D covers it for diabetes only; Medicaid coverage varies by state.

Table of contents

1. The short answer by plan type
2. Why diagnosis on the prescription is the single biggest factor
3. Commercial insurance: what coverage looks like in practice
4. Medicare Part D and Ozempic
5. Medicaid: a state-by-state patchwork
6. TRICARE, VA, and federal employee plans
7. Prior authorization: what your provider has to prove
8. What to do if your plan denies coverage
9. The Novo Nordisk savings card and patient assistance program
10. The compounded semaglutide alternative
11. How to verify your specific Ozempic coverage in 10 minutes
12. FAQ
13. Sources
14. Footer disclaimers

The short answer by plan type

Coverage depends on three things: the type of insurance you have, the diagnosis on your prescription, and whether prior authorization gets approved.

Plan type	Diabetes coverage	Weight-loss coverage
Commercial PPO/HMO (employer)	Usually yes (Tier 3/4)	Almost never
Marketplace ACA plan	Usually yes (Tier 3/4)	Almost never
Medicare Part D	Yes (specialty tier)	No (statutory exclusion)
Medicaid	State-dependent (around 80%)	Rarely
TRICARE	Yes for diabetes with PA	No
VA	Yes for diabetes	No
No insurance	N/A	N/A (cash $940 to $1,150/mo)

The rest of this article unpacks each row. The short version: if you have type 2 diabetes and any reasonable insurance plan, the answer is almost always yes with paperwork. If you want Ozempic for weight loss alone, the answer is almost always no, and Wegovy or compounded semaglutide are the practical options.

Why diagnosis on the prescription is the single biggest factor

Ozempic is FDA-approved for one thing: improving blood-sugar control in adults with type 2 diabetes. The same molecule (semaglutide) is sold as Wegovy at higher doses for chronic weight management.

Insurance plans price Ozempic based on the diagnosis code (ICD-10) your provider writes on the prescription. If the code is E11.x (type 2 diabetes mellitus), the plan applies its diabetes-medication rules. If the code is E66.x (obesity) or Z68.x (BMI), the plan applies its weight-loss-medication rules, which are usually much more restrictive.

Some plans go a step further and require evidence of an A1C above 6.5% or a documented diabetes diagnosis longer than three months. Plans that previously covered Ozempic for "pre-diabetes" or insulin resistance have largely tightened those rules in 2024 to 2026 because of demand pressure.

Writing a diabetes diagnosis code on a chart for a patient who does not have diabetes is insurance fraud. Reputable providers will not do it. If you do not have diabetes, the realistic insurance question is whether your plan covers Wegovy, not whether it covers Ozempic.

Commercial insurance: what coverage looks like in practice

About 95% of commercial plans (employer PPOs, HMOs, marketplace plans) cover Ozempic for type 2 diabetes as of Q1 2026. The remaining 5% are typically high-deductible plans with restrictive specialty-drug formularies.

What "covered" actually means for a patient:

• Formulary tier. Ozempic usually lands on Tier 3 (non-preferred brand) or Tier 4 (specialty). A handful of large employer plans have negotiated Tier 2 placement.
• Prior authorization. Most plans require PA. The provider submits documentation showing diabetes diagnosis, A1C, prior medication trials, and medical necessity. Approval takes 3 to 14 days.
• Step therapy. Some plans require you to try and fail metformin first, sometimes a second oral agent like a sulfonylurea. If you have already taken metformin, your provider notes it on the PA form and the requirement is met.
• Quantity limits. Most plans limit fills to one pen per 28 to 30 days. Higher quantities require additional PA.
• Copay or coinsurance. Ranges from $25 (Tier 2 with a low-copay plan) to over $400 (Tier 4 with 30% coinsurance).

A 2024 GoodRx survey found 47% of new Ozempic prescriptions required prior authorization, and 22% of those PAs were denied on first submission. Most denials are reversed on appeal when the provider sends additional documentation.

Medicare Part D and Ozempic

Medicare Part D plans cover Ozempic for type 2 diabetes. Coverage details:

• Tier: Specialty tier (Tier 4 or 5 on most plan formularies).
• Copay: Typically $250 to $500 per month after the deductible. Coverage gap (donut hole) increases the cost in mid-year for some patients.
• Prior authorization: Most Part D plans require PA documenting type 2 diabetes.
• Step therapy: Many plans require a metformin trial first.
• Manufacturer savings card: Medicare patients are not eligible for the Novo Nordisk savings card. Federal anti-kickback rules block manufacturer copay assistance for any government-funded plan.

Medicare does not cover Ozempic for weight management. The 2003 Medicare Modernization Act explicitly excluded "agents when used for anorexia, weight loss, or weight gain" from Part D coverage. Bills to expand Medicare to cover anti-obesity medications (the Treat and Reduce Obesity Act, TROA) have been proposed every Congress since 2013 and have not passed.

For Medicare patients who cannot afford Ozempic, the Novo Nordisk Patient Assistance Program (PAP) provides free Ozempic to qualifying low-income patients regardless of Medicare status.

Medicaid: a state-by-state patchwork

Medicaid coverage of Ozempic varies dramatically by state. As of 2026:

• Cover for diabetes with PA: about 80% of state Medicaid programs.
• Cover for diabetes without PA: rare (a few preferred-drug-list states).
• Cover for weight loss: 16 states cover at least one anti-obesity medication; only about 8 specifically include Wegovy or Saxenda. Almost none cover Ozempic off-label for weight loss.

States that have publicly expanded weight-loss medication coverage in Medicaid include California, Pennsylvania, Massachusetts, Michigan, and Minnesota, with varying conditions.

Each state's Medicaid managed-care organization (MCO) publishes a preferred drug list. Searching "[your state] Medicaid PDL semaglutide" usually returns the relevant document. PA forms are listed alongside the PDL.

TRICARE, VA, and federal employee plans

TRICARE. Covers Ozempic for type 2 diabetes with prior authorization. Copays follow standard TRICARE pharmacy benefit rules ($14 to $76 depending on retail vs mail-order and beneficiary category). Does not cover Ozempic or Wegovy for weight loss.

VA. The VA covers Ozempic for diabetes through the VA pharmacy. Veterans pay the standard VA copay ($11 for a 30-day supply, $33 for 90 days), depending on priority group. The VA does not cover GLP-1 medications for weight loss alone.

Federal Employee Health Benefits (FEHB) plans. FEHB plans like Blue Cross Blue Shield Federal cover Ozempic for diabetes with PA. Some FEHB plans have started covering Wegovy for weight loss as of 2024 with BMI and comorbidity requirements.

Prior authorization: what your provider has to prove

A typical Ozempic PA form asks for:

1. Diagnosis code: E11.x (type 2 diabetes), confirmed by lab results.
2. A1C: usually a recent value showing inadequate control on current therapy. Most plans require A1C above 7.0% to start, though this varies.
3. Prior medications: documentation of metformin trial (or contraindication), and sometimes a second oral agent.
4. BMI: some plans require BMI above 27 or 30 for additional weight-related justification.
5. Comorbidities: cardiovascular disease, kidney disease, or other complications strengthen the medical necessity case.

PA approval timelines:

• Standard review: 3 to 7 business days
• Expedited review: 24 to 72 hours (used when delay would harm health)
• Appeal of denial: 30 to 60 days

If your provider submits a PA and you do not hear back within 7 business days, call the plan's pharmacy benefit manager (PBM) directly. The number is on the back of your insurance card under "pharmacy benefits."

What to do if your plan denies coverage

A denial is not a final answer. Three paths forward:

1. Appeal with additional documentation. About half of Ozempic denials are overturned on first appeal when the provider adds A1C trend data, comorbidity records, or evidence of failed alternatives. Appeals are filed by the prescribing provider's office.

2. Request a formulary exception. If Ozempic is not on the plan's formulary at all, your provider can request a formulary exception by documenting why other covered alternatives are not appropriate. Approval rates are around 30% but worth attempting.

3. Switch to a covered alternative. If your plan covers a different GLP-1 (like dulaglutide) on a lower tier, your provider can prescribe that instead. Clinical effects are similar, though not identical, across the GLP-1 class.

4. Use the Novo Nordisk savings card or PAP. Detailed below.

5. Consider compounded semaglutide. For patients without coverage or with high copays, compounded semaglutide is the most common cash-pay alternative.

The Novo Nordisk savings card and patient assistance program

Novo Nordisk runs two separate programs.

Ozempic Savings Card (commercial insurance). Reduces eligible commercial copays to as little as $25 per fill, up to roughly $150 of benefit per fill, for up to 24 fills. Eligibility requires:

• Commercial insurance that covers Ozempic
• Prescription for type 2 diabetes
• U.S. resident
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government program

About 20% to 25% of new Ozempic patients qualify based on Novo Nordisk published data.

Novo Nordisk Patient Assistance Program (PAP, NovoCare). Provides free Ozempic for up to 12 months, renewable, to qualifying low-income patients. Eligibility requires:

• Income below 400% of federal poverty level (about $60,240 for an individual, $124,800 for a family of four)
• U.S. resident or legal U.S. resident
• No prescription drug coverage, or coverage that does not cover Ozempic
• Diagnosis of type 2 diabetes

Provider signs the medical necessity portion. Approval takes 5 to 10 business days. Free drug is shipped directly to the patient's address.

The PAP is the most under-used Ozempic assistance program. Many providers do not routinely mention it. Patients who think they may qualify should ask their provider to submit the application.

The compounded semaglutide alternative

For patients without coverage or whose copay is unsustainable, compounded semaglutide is the most common alternative. Compounded semaglutide is the same active ingredient prepared by a state-licensed compounding pharmacy in response to an individual prescription.

Pricing for compounded semaglutide:

• FormBlends compounded semaglutide: $179 to $279 per month
• Other compounding-pharmacy telehealth: $199 to $499 per month
• Local 503A compounding pharmacy: $150 to $350 per month

Important context:

• Compounded semaglutide is not FDA-approved.
• It is not interchangeable with brand-name Ozempic.
• It is drawn from a vial with a U-100 insulin syringe rather than delivered by a prefilled pen.
• It bypasses insurance, so there is no PA paperwork.

Compounded semaglutide makes sense when insurance does not cover Ozempic, the copay is over $200 per month, or you do not qualify for the savings card or PAP. Brand-name Ozempic still makes sense when your copay is under $50, you qualify for the PAP, or you strongly prefer FDA-approved drugs.

For a fuller comparison, see /articles/answers-hub/ozempic-cost-at-walmart-with-insurance-what-youll-actually-pay-with-insurance/ and /articles/glp1-hub/compounded-semaglutide-for-weight-loss-complete-guide-2026.

How to verify your specific Ozempic coverage in 10 minutes

Step 1. Find your insurance member ID and pharmacy benefit manager (PBM) phone number. Both are on the back of your insurance card.

Step 2. Call the PBM. Say "I want to check coverage for Ozempic, generic name semaglutide, for type 2 diabetes." Ask three questions:

• Is Ozempic on the formulary?
• What tier and what is my copay?
• Is prior authorization required, and what are the criteria?

Step 3. Log into your insurance member portal. Find the formulary document. Search "semaglutide." The formulary listing tells you tier, PA status, and quantity limits.

Step 4. Run a test claim at a pharmacy. Most retail pharmacies will run an electronic claim against your insurance for free, before you fill, and tell you the exact copay.

Step 5. If insurance is denied or copay is too high, check eligibility for the savings card (commercial insurance, diabetes, no government plan) and the PAP (low income, no/inadequate coverage).

This 10-minute process prevents the most common cost surprise: showing up at the pharmacy expecting $25 and learning the copay is $400.

FAQ

Does insurance cover Ozempic for type 2 diabetes? Yes, in most cases. About 95% of commercial plans, all Medicare Part D plans, and around 80% of state Medicaid programs cover Ozempic for type 2 diabetes, usually with prior authorization. Copays range from $25 to $500 per month depending on the plan.

Does insurance cover Ozempic for weight loss? Almost never. Ozempic is FDA-approved only for type 2 diabetes. The same molecule for weight loss is sold as Wegovy, which a small number of plans cover with strict criteria. Some plans deny Ozempic outright when the diagnosis code indicates obesity rather than diabetes.

Why does my insurance not cover Ozempic? Common reasons: the prescription is for weight loss (off-label), prior authorization was not submitted or was denied, you have not tried metformin first (step therapy), the plan excludes GLP-1 medications, or you have not yet met your deductible.

Does Medicare cover Ozempic? Yes for type 2 diabetes through Medicare Part D, no for weight loss. Specialty tier copays are typically $250 to $500 per month. Medicare patients are not eligible for the Novo Nordisk savings card due to federal anti-kickback rules.

Does Medicaid cover Ozempic? Coverage varies by state. About 80% of state Medicaid programs cover Ozempic for type 2 diabetes with prior authorization. Coverage for weight loss is rare; only a handful of states cover any anti-obesity medication for Medicaid enrollees.

How much is Ozempic with insurance? Typically $25 to $500 per month after PA approval. The most common range is $40 to $150 for patients on commercial plans with Tier 3 placement and a met deductible. Patients on a high-deductible plan pay full negotiated rate until the deductible is met.

How much is Ozempic without insurance? Cash price at retail pharmacies runs $940 to $1,150 per month for any dose. With a GoodRx coupon, expect $850 to $1,000. Compounded semaglutide is a cash alternative starting around $179 per month.

Will insurance cover Ozempic if I have prediabetes? Usually no. Most plans require an A1C above 6.5% with a confirmed type 2 diabetes diagnosis. Some plans cover metformin for prediabetes but not GLP-1 medications. Coverage criteria for GLP-1s in prediabetes have tightened since 2023.

How do I get insurance to cover Ozempic? Have your provider submit a prior authorization with documentation of type 2 diabetes diagnosis, A1C, prior medication trials, and any comorbidities. If denied, file an appeal with additional documentation. Approval rates improve significantly on first appeal.

Can I use the Novo Nordisk savings card with my insurance? Yes, if you have commercial insurance, the prescription is for diabetes, you are a U.S. resident, and you are not on Medicare, Medicaid, TRICARE, or VA. The card reduces eligible copays to as little as $25 per fill, up to about $150 of benefit per fill.

Does insurance cover Ozempic for PCOS? Rarely, because PCOS is not an FDA-approved indication for Ozempic. Some plans cover Ozempic if the patient also has type 2 diabetes alongside PCOS. Most off-label PCOS prescriptions for GLP-1 medications are paid out of pocket or through compounded semaglutide.

Is compounded semaglutide cheaper than Ozempic with insurance? For patients with high copays or no coverage, yes. FormBlends compounded semaglutide starts at $179 per month against $940-plus cash for Ozempic. For patients with insurance and a copay under $100, brand-name Ozempic with the savings card may be cheaper.

Sources

1. Novo Nordisk. Ozempic (semaglutide injection) Prescribing Information, revised 2024.
2. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
3. Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844.
4. American Diabetes Association. Standards of Care in Diabetes 2025. Diabetes Care. 2025;48(Suppl 1).
5. GoodRx Research. Prior authorization rates for GLP-1 medications, 2024 survey.
6. Centers for Medicare and Medicaid Services. Medicare Part D drug coverage rules and exclusions, 2026.
7. Kaiser Family Foundation. State Medicaid coverage of obesity medications: a 50-state survey, 2024.
8. Defense Health Agency. TRICARE Pharmacy Formulary, 2026 edition.
9. Department of Veterans Affairs. VA National Formulary, 2026.
10. Office of Personnel Management. FEHB Pharmacy Benefit Comparison, 2026.
11. Novo Nordisk. NovoCare Patient Assistance Program eligibility and enrollment, 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Medicare, Medicaid, TRICARE, and the VA are programs of the United States government. GoodRx is a trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies or programs.